ArticleBiomarker insights2026
Assessment of Brain-Specific and Neuroendocrine Biomarkers for Intracerebral Hemorrhage Diagnosis: A Prospective Cohort Study.
Article in Biomarker insights, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Background and Purpose: The timing of diagnosis is a critical factor that significantly impacts medical treatment and patient outcomes in individuals with intracerebral hemorrhage (ICH). The study primarily aimed to evaluate the diagnostic potential of four brain-specific biomarkers, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), tau, and ubiquitin C-terminal hydrolase-L1 (UCH-L1) to differentiate CT-confirmed ICH patients from healthy controls. Secondary aims included comparing results between younger (18-59 years) and older (≥60 years) ICH patients and exploring neuroendocrine hormone levels (adrenocorticotropic hormone [ACTH], agouti-related peptide [AgRP], ciliary neurotrophic factor [CNTF], and growth hormone [GH]) as potential diagnostic tools. Methods: Serum samples were collected from consecutive adult patients with CT-confirmed ICH diagnoses on days 1 (first 24 hours), 2, 3, 7, and 14 for biomarker analyses in a pilot study. A total of 71 patients and 30 healthy controls were included in the analysis. Results: Serum concentrations of four brain-specific biomarkers demonstrated significant differentiation between ICH patients and controls at all assessed time points (Days 1, 2, 3, 7, and 14; all p<0.05), with similar significant elevations observed for NfL, tau, and UCH-L1. Day 1 GFAP levels were markedly higher in ICH patients (median 9598 pg/mL compared with healthy controls (39.2 pg/mL; p<0.05). No significant differences were found between young and aged adult ICH subgroups. Neuroendocrine ACTH and AgRP levels were significantly higher in ICH patients compared to controls on both measured time points (Days 1 and 7). Conclusions: The study's findings suggest that GFAP, NfL, tau, UCH-L1, ACTH, and AgRP exhibit potential as biomarkers for differentiating spontaneous ICH patients from healthy controls. However, given the limitations of the current study design, these findings should be interpreted with caution and cannot be expected to translate directly into clinical practice. Further research is needed to assess these biomarkers' roles in distinguishing stroke types and predicting ICH outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.